Toroph Pharmaceutical Import Profile — Kazakhstan (DGFT 2022–2026)

Name: Toroph Pharmaceutical Import Records from India — 2 Products, $219.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Toroph — Pharmaceutical Importer Profile (2026) | 2 Products, $219.0K Trade | TransData Nexus

Toroph

Pharmaceutical Importer · Kazakhstan · Advanced Oncology Focus · $219.0K Total Trade · DGFT Verified

Toroph is a pharmaceutical importer based in Kazakhstan with a total trade value of $219.0K across 2 products in 1 therapeutic categories. Based on 8 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Toroph sources from 1 verified Indian supplier, with Bdr Pharmaceuticals International Private Limited accounting for 100.0% of imports.

Toroph — Import Portfolio & Supplier Network

Toroph import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Toroph?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Bdr Pharmaceuticals International Private Limited	$514.4K	20	100.0%

Toroph sources from 1 verified Indian supplier across 20 distinct formulations. The sourcing is highly concentrated — Bdr Pharmaceuticals International Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Abirateron acetate 500MG tablets	$50.0K	1
Enzalutamide capsules 40MG bdenza other tax document mh1160000390 dtd.	$50.0K	1
Lapatinib tablets 250MG (lanib 250) (other) ((tax inv mh1160000496 dtd. 19.01.2024	$50.0K	1
Enzalutamide capsules 40MG (bdenza) (other)(lut(arn)no: ad270324101144o dt: 15/03/2024)(tax	$50.0K	1
Enzalutamide capsules 40MG (bdenza) (other) ((tax inv mh1160000496 dtd. 19.01.2024	$50.0K	1
Enzalutamide capsules 40MG (bdenza) (other) (tax inv# mh2411600133 dt: 24.06.2024)	$50.0K	1
Abiraterone acetate 500MG (bdron 500) (other) (tax inv# mh2411600133dt: 24.06.2024)	$50.0K	1
Lapatinib tablets 250MG (lanib 250) (other) (tax inv#mh2511600019 dt:18.04.2025)	$50.0K	1
Lapatinib tablets 250MG (lanib 250) (other) (tax inv# mh2411600149 dt: 28.06.2024)	$42.7K	1
Lenvatinib 10MG tablets (bdfoie 10) (other) (tax inv# mh2411600634 dt: 27.03.2025)	$39.0K	1
Bdron 250 MG (others)(tax invmh1160000391 dt27.11.2023)	$22.2K	1
Lenvatinib 4MG tabs (bdfoie 4MG) (other) (tax inv#mh2511600038 dt:29.04.2025)	$10.5K	1
Bdron 250 MG 6 bottles as free sample (tax invmh1160000391 dt27.11.2023)	$0	1
Lapatinib tablets 250MG (lanib 250) 6 Pack sample as	$0	1
Abirateron acetate 500MG (bdron 500)	$0	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lapatinib	Advanced Oncology	$169.5K	5	1.9%	3
2	Lenvatinib	Advanced Oncology	$49.5K	3	2.3%	5

Toroph imports 2 pharmaceutical products across 1 categories into Kazakhstan totaling $219.0K.

Toroph — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Toroph is a pharmaceutical importer based in Almaty, Kazakhstan, specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the distribution of oncology medications within Kazakhstan, focusing on advanced oncology treatments. Toroph's operations are characterized by a concentrated product portfolio, with a significant emphasis on specific therapeutic areas.

2Distribution Network

While specific details about Toroph's warehouse locations and logistics capabilities are not publicly disclosed, the company's import activities suggest a well-established distribution network within Kazakhstan. The focus on advanced oncology products indicates a strategic alignment with healthcare facilities and pharmacies that cater to specialized medical needs. Toroph's logistics operations are likely designed to ensure timely and efficient delivery of critical medications across the country.

3Industry Role

Toroph functions primarily as a pharmaceutical importer, sourcing finished formulations from international suppliers, particularly from India. The company's role is central to the supply chain, ensuring the availability of essential oncology medications in Kazakhstan. By focusing on advanced oncology treatments, Toroph addresses a critical segment of the pharmaceutical market, catering to the needs of patients requiring specialized cancer therapies.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Toroph

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Toroph's sourcing strategy is highly concentrated, with a total import value of $219,000 USD from India across eight shipments. The top two products imported are Lapatinib ($169,000 USD) and Lenvatinib ($50,000 USD), accounting for 1.9% and 2.3% of the total import value, respectively. This concentration suggests a strategic focus on specific oncology treatments, potentially leveraging favorable pricing and supply chain efficiencies from a single supplier. However, such dependency on a single supplier may pose risks related to supply chain disruptions or changes in supplier terms.

2Supply Chain Resilience

The resilience of Toroph's supply chain is closely tied to its relationship with BDR Pharmaceuticals International Private Limited, the sole supplier identified in customs records. The limited number of suppliers may expose Toroph to risks associated with supply chain disruptions, such as production delays or geopolitical issues affecting trade routes. To mitigate these risks, Toroph could consider diversifying its supplier base and establishing relationships with additional manufacturers to ensure a more robust supply chain.

3Strategic Implications

Importing Pharmaceuticals into Kazakhstan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Kazakhstan

1Regulatory Authority & Framework

The primary regulatory body overseeing pharmaceutical imports in Kazakhstan is the Ministry of Health. The Code of the Republic of Kazakhstan on People's Health and Healthcare System, enacted on September 18, 2009, provides the legal framework for the importation of medicines and medical devices. According to this code, the importation of drugs, medical devices, and medical equipment into Kazakhstan is permitted only if the products have passed state registration in the country. Exceptions are made for specific cases, such as clinical research or life-saving treatments, where unregistered products may be imported under special authorization. (wipolex-res.wipo.int)

2Import Licensing & GMP

Importers of pharmaceutical products in Kazakhstan must obtain a license for wholesale trading of pharmaceutical products or be included in the register of entities of public health services, administering wholesale trading of medical products, upon notification of commencement of business. Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards recognized by the Ministry of Health. The importation of unregistered medicines is allowed under specific conditions, such as for clinical research or life-saving treatments, provided that the products meet GMP standards and are authorized by the relevant authorities. (wipolex-res.wipo.int)

Toroph — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Toroph's focus on advanced oncology products, specifically Lapatinib and Lenvatinib, aligns with the growing demand for specialized cancer treatments in Kazakhstan. The importation of these medications addresses critical therapeutic needs, providing patients with access to essential therapies. The strategic selection of these products suggests a targeted approach to meet the healthcare demands of the population, particularly in the oncology sector.

2Sourcing Profile

Toroph's sourcing strategy is centered on importing generic oncology drugs from India, leveraging the country's established pharmaceutical manufacturing capabilities and cost advantages. The focus on finished pharmaceutical formulations indicates a preference for ready-to-use products that meet the regulatory standards of Kazakhstan. This approach allows Toroph to efficiently supply the market with essential oncology medications while maintaining compliance with local regulations.

3Market Positioning

By specializing in advanced oncology treatments, Toroph positions itself as a key supplier to hospitals, specialized clinics, and pharmacies that cater to cancer patients in Kazakhstan. The company's product mix suggests a focus on the hospital and specialized healthcare segments, where the demand for specific oncology therapies is high. Toroph's role in the supply chain is crucial for ensuring the availability of these specialized medications to meet the needs of the healthcare system.

Seller's Guide — How to Become a Supplier to Toroph

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Kazakhstani market by partnering with Toroph. Given Toroph's concentrated sourcing strategy, introducing additional oncology products could complement its existing portfolio and meet the evolving needs of the market. Establishing a relationship with Toroph would require ensuring product quality, compliance with regulatory standards, and the ability to meet the logistical demands of the Kazakhstani market.

2Requirements & Qualifications

Indian exporters seeking to supply Toroph and the broader Kazakhstani market must ensure that their products are registered with the Ministry of Health of Kazakhstan. Compliance with GMP standards recognized by the Ministry is mandatory. Additionally, products must meet quality control requirements, including batch testing and stability assessments, and adhere to labeling regulations, with information provided in the Kazakh language. Exporters should also be prepared to navigate the import licensing process and ensure that their products are authorized for sale in Kazakhstan.

3How to Approach

Frequently Asked Questions — Toroph

What products does Toroph import from India?

Toroph imports 2 pharmaceutical products across 1 categories. Top imports: Lapatinib ($169.5K), Lenvatinib ($49.5K).

Who supplies pharmaceuticals to Toroph from India?

Toroph sources from 1 verified Indian suppliers. The primary supplier is Bdr Pharmaceuticals International Private Limited (100.0% of imports, $514.4K).

What is Toroph's total pharmaceutical import value?

Toroph's total pharmaceutical import value from India is $219.0K, based on 8 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Toroph focus on?

Toroph imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Toroph Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.